University of Hull logo

Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

Agarwal, Vijay; Lind, Michael J.; Cawkwell, Lynn

Authors

Vijay Agarwal

Professor Michael Lind M.J.Lind@hull.ac.uk
Foundation Professor of Oncology/ Head of the Joint Centre for Cancer Studies

Abstract

The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant pleural mesothelioma samples and therefore may be a potential therapeutic target. Targeted EGFR therapy has been successful in non-small cell lung cancer using small molecule tyrosine kinase inhibitors and in colorectal cancer using monoclonal anti-EGFR antibodies. However, phase II clinical trials based on EGFR tyrosine kinase inhibitor therapy have so far not shown promise in mesothelioma. This review includes a background to targeted EGFR treatment strategies, explores putative therapy resistance mechanisms, including the role of predictive biomarkers, and describes the current status of targeted EGFR therapeutic strategies for mesothelioma patients.

Journal Article Type Article
Publication Date 2011-11
Journal Cancer treatment reviews
Print ISSN 0305-7372
Electronic ISSN 1532-1967
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 37
Issue 7
Pages 533-542
Institution Citation Agarwal, V., Lind, M. J., & Cawkwell, L. (2011). Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. Cancer Treatment Reviews, 37(7), (533-542). doi:10.1016/j.ctrv.2010.11.004. ISSN 1532-1967
DOI https://doi.org/10.1016/j.ctrv.2010.11.004
Keywords Oncology; Radiology Nuclear Medicine and imaging; General Medicine
PMID 21183281